<DOC>
	<DOCNO>NCT00000688</DOCNO>
	<brief_summary>To provide information usefulness safety give injection ganciclovir ( DHPG ) treat peripheral cytomegalovirus ( CMV ) retinitis . CMV retinitis important sight-threatening opportunistic infection affect 1 2 every 10 patient AIDS . Results early study suggest 80 percent patient CMV retinitis help receive intravenous dos DHPG .</brief_summary>
	<brief_title>A Randomized , Controlled Study Intravenous Ganciclovir Therapy Peripheral Cytomegalovirus Retinitis Patients With AIDS</brief_title>
	<detailed_description>CMV retinitis important sight-threatening opportunistic infection affect 1 2 every 10 patient AIDS . Results early study suggest 80 percent patient CMV retinitis help receive intravenous dos DHPG . Patients randomly place one two treatment group . In one group , patient receive DHPG twice day , intravenously , 14 day , follow daily dose 14 week . Patients group ( delayed-treatment group ) receive immediate treatment DHPG . Patients group regular ophthalmologic ( eye ) evaluations retinal photograph see retinitis get bad . Patients delayed treatment group receive DHPG occurs .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) patient delayed treatment group receive ganciclovir . Didanosine ( ddI ) may continue initiated patient study . Topical acyclovir . Topical ophthalmics . Aerosolized pentamidine . Patients must : AIDS define CDC criterion confirmation HIV infection ELISA , p24 antigen assay , culture HIV . Retinal lesion great 1500 micron edge optic disc outside major temporal vascular arcade , great 3000 micron fovea . Understanding study provision , willingness sign inform consent form approve appropriate Institutional Review Board Syntex . Life expectancy least 4 month . Exclusion Criteria Coexisting Condition : Patients ocular condition require immediate surgical correction exclude . Concurrent Medication : Excluded first 4 week ganciclovir treatment : Zidovudine ( AZT ) . Excluded : Other investigational drug antimetabolite , alkylating agent , nucleoside analog ( topical ophthalmics permit ) , acyclovir , interferon , foscarnet ( nonnucleoside pyrophosphate analog ) , cytomegalovirus ( CMV ) hyperimmune globulin , cytokine . Patients follow exclude : Immediately sightthreatening retinitis ( = &lt; 1500 micron edge optic disc , inside major temporal vascular arcade , = &lt; 3000 micron fovea ) . Ocular medium opacity ( corneal , lenticular , vitreal ) prevent ophthalmologic photographic retinal assessment . Demonstrated hypersensitivity acyclovir . Prior Medication : Excluded : Previous treatment anticytomegalovirus therapy .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1990</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>